Sharon Mates, Chairman, President & CEO at Intra-Cellular Therapies, Inc. (ITCI), sold 82,682 shares at $30.94 ($2.6M) on 2021-01-04, disclosed to the SEC on 2021-01-05.
Seasonal sale ($2.6M) by Chairman, President & CEO — this insider has traded ITCI in January in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $30.94 | 2,800 | $87K | 3.3% |
| 2 | $30.94 | 6,428 | $199K | 7.7% |
| 3 | $30.94 | 6,428 | $199K | 7.7% |
| 4 | $31.39 | 11,200 | $352K | 13.6% |
| 5 | $31.39 | 27,913 | $876K | 33.9% |
| 6 | $31.39 | 27,913 |
| $876K |
| 33.9% |
| Total | $31.30 avg | 82,682 | $2.6M | 100% |
| Filing → |
| ITCI | SELL | 2024-08-28 | $14.1M | — | Filing → |
| ITCI | SELL | 2024-08-23 | $18.0M | — | Filing → |
| ITCI | SELL | 2024-03-11 | $8.1M | — | Filing → |